<DOC>
	<DOC>NCT01512563</DOC>
	<brief_summary>Paclitaxel covered metal biliary stent extents their patency rate comparing to the Common Covered Metallic Biliary Stent.</brief_summary>
	<brief_title>Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent</brief_title>
	<detailed_description>Paclitaxel covered metal biliary stent(Mira-Cover Biliary Stent) extents their patency rate comparing to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient who is inoperable and/or unresectable cases of pancreatic cancer and/or biliary cancer with mid or distal CBD invasion Among patient of a.,Patient who previously had surgical biliary drainage of plastic stent have eligibility Patient who have life expectancy under 3 months Patient who have severe metastasis of Liver or whole body Patient who previously had surgical biliary drainage</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>drug eluting stent</keyword>
</DOC>